Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Monday, February 23, 2026 at 5:30 p.m. ET / 2:30 p.m. PT to provide a corporate update and discuss fourth-quarter and full-year financial results for the period ended December 31, 2025.
According to the company, the call can be accessed via the Events & Presentations page on Vir Biotechnology's website.
Vir Biotechnology (Nasdaq: VIR) reported positive Phase 2 SOLSTICE results in chronic hepatitis delta showing undetectable HDV RNA (TND) in 88% of combination tobevibart + elebsiran participants evaluated at Week 96 versus 46% with antibody monotherapy at Week 96. No treatment-related Grade ≥3 adverse events were observed in the combination arm. The registrational ECLIPSE program is fully enrolled (ECLIPSE 1 and 3) with ECLIPSE 1 topline expected in Q4 2026 and ECLIPSE 2/3 toplines in Q1 2027. Vir will present Phase 1 VIR-5500 data at ASCO GU 2026. Year-end cash and investments were ~$781M, with runway into Q4 2027 after the Norgine licensing agreement.
Vir Biotechnology (NASDAQ: VIR) announced that CEO Marianne De Backer will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast will be available under Events & Presentations in the company's Investors section and the webcast will be archived for 30 days.
Vir Biotechnology (NASDAQ: VIR) granted Norgine an exclusive commercial license for the combination of tobevibart + elebsiran to treat chronic hepatitis delta in Europe, Australia and New Zealand.
Key terms: an initial reimbursement payment of EUR 55 million, up to EUR 495 million in milestones, tiered mid‑teen to high‑twenties percent royalties, and shared ECLIPSE program costs with Norgine funding ~25% of go‑forward external costs. Vir retains U.S. and other non‑Greater China rights.
Corporate and clinical updates: ECLIPSE 3 enrollment completed; Vir expects existing cash, cash equivalents and investments to extend into Q4 2027 under the current plan. Prior Phase 2 SOLSTICE data showed 66% (21/32) achieved HDV RNA target not detected with the combination and no grade 3+ treatment‑related adverse events.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida.
A live webcast will be available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) reported Week 48 Phase 2 SOLSTICE results showing the monthly combination of tobevibart + elebsiran achieved 66% HDV RNA target not detected (21/32) and ~90% HBsAg <10 IU/mL. ALT normalized in 56% at Week 48. The regimen was well tolerated with no grade 3+ treatment-related adverse events and no treatment-related discontinuations. Data were presented at AASLD The Liver Meeting® and published in the New England Journal of Medicine. Vir’s registrational ECLIPSE program is underway with topline results from ECLIPSE 1–3 expected in Q1 2027. The program holds FDA Breakthrough and Fast Track and EMA PRIME and orphan designations.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London.
A live webcast will be available via the company's Investors & Events page and the presentation will be archived online for 30 days.
Vir Biotechnology (NASDAQ: VIR) reported Q3 2025 results and a corporate update on November 5, 2025. The company ended the quarter with $810.7 million in cash, cash equivalents and investments and expects runway into mid-2027. Clinical highlights include ECLIPSE 1 enrollment completing ~two months ahead of schedule with primary completion expected in Q4 2026 and topline data for ECLIPSE 1–3 expected in Q1 2027. VIR-5500 first patient dosed in an ARPI combination study and a comprehensive VIR-5500 data update is planned for Q1 2026. Q3 financials: revenue $0.2M, R&D $151.5M, SG&A $22.2M, and net loss $163.1M ($1.17/share). A conference call was held November 5, 2025.
Vir Biotechnology (Nasdaq: VIR) announced completion of enrollment in ECLIPSE 1, a Phase 3 trial testing the combination of tobevibart + elebsiran for chronic hepatitis delta (CHD). The company said ECLIPSE 1's last patient is expected to reach the primary endpoint in Q4 2026, with topline data expected in Q1 2027. ECLIPSE 2 and 3 are enrolling and remain on track. The release notes high unmet medical need for CHD, no approved U.S. treatments, and regulatory designations including FDA Breakthrough Therapy and Fast Track and EMA PRIME and orphan drug for the combination.
Vir Biotechnology (Nasdaq: VIR) will provide a corporate update and report third quarter 2025 financial results on November 5, 2025.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. A press release with the corporate update and financial results will be issued shortly after market close and posted on the Investors > News page of Vir Biotechnology's website. A live webcast will be available via the Events & Presentations page; participants must register in advance to receive a unique access link. An archived replay will be available about two hours after the event and remain archived for 30 days.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
